Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome

NCT03614663 is registered in ClinicalTrials.gov with Zynerba Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03614663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03614663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome
Lead sponsor
Zynerba Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
June 12, 2018
Completion date
June 14, 2020
Enrollment
212 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

fragile x syndrome